Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients.

[1]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[2]  P. Pfeiffer,et al.  A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. , 2014, Cancer treatment reviews.

[3]  L. Coussens,et al.  B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. , 2014, Cancer cell.

[4]  Ido D. Weiss,et al.  Inflammation‐induced hepatocellular carcinoma is dependent on CCR5 in mice , 2013, Hepatology.

[5]  B. Necela,et al.  Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs , 2013, The Journal of cell biology.

[6]  N. Halama,et al.  Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration , 2013, Oncoimmunology.

[7]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[8]  A. Palucka,et al.  Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet? , 2013, Science.

[9]  E. Benveniste,et al.  SOCS3 Deficiency Promotes M1 Macrophage Polarization and Inflammation , 2012, The Journal of Immunology.

[10]  M. Lisanti,et al.  CCR5 antagonist blocks metastasis of basal breast cancer cells. , 2012, Cancer research.

[11]  J. Pollard,et al.  New tricks for metastasis-associated macrophages , 2012, Breast Cancer Research.

[12]  V. Seshan,et al.  A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis , 2012, Cell.

[13]  C. Drake,et al.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.

[14]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[15]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[16]  G. Dranoff,et al.  Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.

[17]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[18]  M. Poidinger,et al.  Protumoral role of monocytes in human B-cell precursor acute lymphoblastic leukemia: involvement of the chemokine CXCL10. , 2012, Blood.

[19]  Alicia González-Martín,et al.  CCR5 in cancer immunotherapy: More than an “attractive” receptor for T cells , 2012, Oncoimmunology.

[20]  Yibin Kang,et al.  Unravelling the complexity of metastasis — molecular understanding and targeted therapies , 2011, Nature Reviews Cancer.

[21]  Axel Benner,et al.  Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. , 2011, Cancer research.

[22]  Shih-Hwa Chiou,et al.  SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. , 2011, Gastroenterology.

[23]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[24]  Ana Rouzaut,et al.  Direct Effects of Type I Interferons on Cells of the Immune System , 2011, Clinical Cancer Research.

[25]  M. Koch,et al.  Natural Killer Cells are Scarce in Colorectal Carcinoma Tissue Despite High Levels of Chemokines and Cytokines , 2011, Clinical Cancer Research.

[26]  M. Kloor,et al.  Quantification of prognostic immune cell markers in colorectal cancer using whole slide imaging tumor maps. , 2010, Analytical and quantitative cytology and histology.

[27]  J. Banchereau,et al.  Assessing oncologic benefit in clinical trials of immunotherapy agents. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  G. Trinchieri,et al.  Type I interferon: friend or foe? , 2010, The Journal of experimental medicine.

[29]  L. Ellis,et al.  Finding the tumor copycat: Therapy fails, patients don't , 2010, Nature Medicine.

[30]  Zlatko Trajanoski,et al.  Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. , 2010, Gastroenterology.

[31]  Niels Grabe,et al.  Estimation of Immune Cell Densities in Immune Cell Conglomerates: An Approach for High-Throughput Quantification , 2009, PloS one.

[32]  Jing Xu,et al.  Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1 , 2009, The Journal of experimental medicine.

[33]  C. Klein,et al.  Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.

[34]  I. Judson,et al.  Clinical Benefit of New Targeted Agents in Phase I Trials in Patients with Advanced Colorectal Cancer , 2009, Oncology.

[35]  Qiang Zhou,et al.  Expression of Macrophage Migration Inhibitory Factor by Neuroblastoma Leads to the Inhibition of Antitumor T Cell Reactivity In Vivo1 , 2008, The Journal of Immunology.

[36]  L. Zitvogel,et al.  The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.

[37]  G. Muirhead,et al.  Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. , 2008, British journal of clinical pharmacology.

[38]  L. Coussens,et al.  Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007, Breast Cancer Research.

[39]  Drew M. Pardoll,et al.  Immunostimulatory monoclonal antibodies for cancer therapy , 2007, Nature Reviews Cancer.

[40]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[41]  R. Orentas,et al.  Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. , 2006, Cytokine.

[42]  David A. Price,et al.  Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity , 2005, Antimicrobial Agents and Chemotherapy.

[43]  M. Kinouchi,et al.  Selective infiltration of CCR5+CXCR3+ T lymphocytes in human colorectal carcinoma , 2005, International journal of cancer.

[44]  M. Kloor,et al.  T25 repeat in the 3' untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. , 2005, Cancer Research.

[45]  M. Oppermann.  Chemokine receptor CCR5: insights into structure, function, and regulation. , 2004, Cellular signalling.

[46]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[47]  H. Signorelli.  Blockade of Lymphocyte Chemotaxis in Visceral Graft-Versus-Host Disease , 2013 .

[48]  R. Pearson,et al.  Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer , 2010 .

[49]  M. Kloor,et al.  The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. , 2009, Cancer immunity.

[50]  M. Smyth,et al.  Chemokine-chemokine receptors in cancer immunotherapy. , 2009, Immunotherapy.

[51]  A. Albini,et al.  The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation , 2007, Nature Protocols.